Comments
Lupin Limited introduced Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe, in the United States market. This launch marks Lupin’s entry into the peptide-based injectable segment. The product has received approval from the United States Food and Drug Administration (US FDA) and is a generic equivalent to the reference listed drug (RLD), Ganirelix Acetate Injection, 250 mcg/0.5 mL, manufactured by Organon USA LLC. Ganirelix Acetate Injection is indicated for inhibiting premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
- Also read: Lupin receives USFDA approval for Propranolol Hydrochloride extended-release capsules USP
The company said that Ganirelix Acetate Injection is expected to address market opportunity, with estimated annual sales of $87 million in the U.S. as of December 2023 (IQVIA MAT data).
Lupin Limited, headquartered in Mumbai, India, is a pharmaceutical company. The company develops and commercialises branded and generic formulations, biotechnology products, and APIs across various therapeutic areas. Lupin majors in the cardiovascular, anti-diabetic, and respiratory segments and has a strong presence in other areas such as anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health.
The company’s shares fell 0.46 per cent to ₹1,602.25 at 1.54 pm on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.